This article was originally published in The Gray Sheet
Executive SummaryGains FDA marketing clearance for the automated CryoSeal system for production of cryoprecipitated AHF anti-hemophilic factor, production of which represents a $100 mil. market, according to the company. The firm touts the system's ability to produce AHF on-site within an hour, versus two or three days with traditional manual production. Clinical trials in support of additional indications for producing autologous fibrin glue and autologous platelet derived growth factors will begin in late 1999, Thermogenesis says
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.